FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221045873> ?p ?o ?g. }

• W4221045873 endingPage "15" @default.
• W4221045873 startingPage "P2" @default.
• W4221045873 abstract "Abstract Background: The addition of neoadjuvant platinums to standard chemotherapy regimens for triple negative breast cancer (TNBC) improves rates of pathologic complete response (pCR). Our prior trial combining carboplatin (CAR) with liposomal doxorubicin (DOX) for metastatic TNBC showed good response rates with minimal side effects and allows for higher platinum dosing. We hypothesized that the doublet of DOX+CAR is effective and tolerable in the neoadjuvant setting for TNBC and tumor genomics may identify biomarkers of complete response and actionable targets. Methods: A phase II single arm trial was conducted for patients (pts) diagnosed with stage II-III TNBC. Patients received 4 cycles of neoadjuvant carboplatin (AUC 5) and liposomal doxorubicin (30mg/m2) administered every 28 days, then underwent definitive breast surgery followed by 12 weeks of adjuvant paclitaxel 80 mg/m2 administered weekly. Primary and secondary clinical endpoints were rate of pCR and two year recurrence free survival (RFS) and overall survival (OS), respectively. Cardiac safety of the combination was assessed. Fresh residual tumor samples were obtained at time of surgery for generation of patient derived xenografts (PDX). Whole genome sequencing (WGS) and RNA sequencing will be performed to evaluate specific patterns of small-variant mutations and patterns of structural variants to identify which patients are likely to have pCR. Results: From 2/2015 to 6/2021, 62 pts were enrolled, 8 pts withdrew consent either prior to treatment or completion of neoadjuvant therapy and/or surgery. Median age of the cohort was 55.4 years. There was high participation by under-represented groups: 17.0% African American, 20.8% Asian, 13.2% Hispanic. Most histologies were invasive ductal carcinoma, but included apocrine, pleomorphic lobular, and metaplastic subtypes. 53 pts completed all 4 cycles of neoadjuvant DOX+CAR, followed by definitive surgery; 1 pt progressed after 1 cycle and proceeded to surgery thereafter. 30.2% (16) pts achieved pCR, and residual cancer burden (RCB) will be reported in patients with residual disease. Of the 53 pts who completed 4 cycles of treatment, 5 pts progressed (recurrence or death) within two years from time of surgery (4 distant and 1 local recurrence), yielding the 2-year recurrence-free-survival rate of 90.3% (95%CI 81.0%, 99.6%). The most common toxicities during DOX+CAR were grade 1 fatigue in 50 pts (92.6%), grade 1 anemia in 44 pts (81.5%), and grade 3/4 neutropenia in 16 pts (29.6%); these pts received GCSF support with subsequent cycles; febrile neutropenia occurred in 1 pt (1.9%) in this group. Only 10 pts (18.5%) had grade 1 alopecia, 5 pts (9.3%) had grade 2 alopecia, 2 pts (3.7%) had grade 3 thrombocytopenia. There were no delays in treatment due to cardiotoxicity or complications from surgical healing. Of the 37 pts who had residual disease, PDX was attempted in 21 pts, and 16 (76%) PDX were established, including those for 4 patients experiencing recurrence. WGS and RNA sequencing data from pre-treatment and residual disease samples will be analyzed and reported.Conclusion: 4 cycles of neoadjuvant DOX+CAR achieved rate of pCR similar to standard regimens and has good tolerability. Post chemotherapy PDX is feasible and may help identify targeted approaches for patients with resistant disease. These results warrant further evaluation of this combination for early stage TNBC. Citation Format: Nancy Chan, Shou-en Lu, Yue Wang, Gregory M Riedlinger, Coral Omene, Mridula George, Jyoti Malhotra, Maria Kowzun, Firas G Eladoumikdachi, Lindsay B Potdevin, Shicha Kumar, Kant Matsuda, Shruti Desai, Nayana Patel, Deborah L Toppmeyer, Shridar Ganesan, Kim Hirshfield. Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of early stage triple negative breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-12-15." @default.
• W4221045873 created "2022-04-03" @default.
• W4221045873 creator A5007869493 @default.
• W4221045873 creator A5008527277 @default.
• W4221045873 creator A5009395077 @default.
• W4221045873 creator A5018355368 @default.
• W4221045873 creator A5018754593 @default.
• W4221045873 creator A5025093874 @default.
• W4221045873 creator A5031621111 @default.
• W4221045873 creator A5033632697 @default.
• W4221045873 creator A5035450321 @default.
• W4221045873 creator A5044773708 @default.
• W4221045873 creator A5048331793 @default.
• W4221045873 creator A5061989008 @default.
• W4221045873 creator A5072435637 @default.
• W4221045873 creator A5073661192 @default.
• W4221045873 creator A5081735541 @default.
• W4221045873 creator A5082786477 @default.
• W4221045873 creator A5087464264 @default.
• W4221045873 date "2022-02-15" @default.
• W4221045873 modified "2023-10-11" @default.
• W4221045873 title "Abstract P2-12-15: Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of early stage triple negative breast cancer" @default.
• W4221045873 doi "https://doi.org/10.1158/1538-7445.sabcs21-p2-12-15" @default.
• W4221045873 hasPublicationYear "2022" @default.
• W4221045873 type Work @default.
• W4221045873 citedByCount "0" @default.
• W4221045873 crossrefType "journal-article" @default.
• W4221045873 hasAuthorship W4221045873A5007869493 @default.
• W4221045873 hasAuthorship W4221045873A5008527277 @default.
• W4221045873 hasAuthorship W4221045873A5009395077 @default.
• W4221045873 hasAuthorship W4221045873A5018355368 @default.
• W4221045873 hasAuthorship W4221045873A5018754593 @default.
• W4221045873 hasAuthorship W4221045873A5025093874 @default.
• W4221045873 hasAuthorship W4221045873A5031621111 @default.
• W4221045873 hasAuthorship W4221045873A5033632697 @default.
• W4221045873 hasAuthorship W4221045873A5035450321 @default.
• W4221045873 hasAuthorship W4221045873A5044773708 @default.
• W4221045873 hasAuthorship W4221045873A5048331793 @default.
• W4221045873 hasAuthorship W4221045873A5061989008 @default.
• W4221045873 hasAuthorship W4221045873A5072435637 @default.
• W4221045873 hasAuthorship W4221045873A5073661192 @default.
• W4221045873 hasAuthorship W4221045873A5081735541 @default.
• W4221045873 hasAuthorship W4221045873A5082786477 @default.
• W4221045873 hasAuthorship W4221045873A5087464264 @default.
• W4221045873 hasConcept C121608353 @default.
• W4221045873 hasConcept C126322002 @default.
• W4221045873 hasConcept C141071460 @default.
• W4221045873 hasConcept C143998085 @default.
• W4221045873 hasConcept C146357865 @default.
• W4221045873 hasConcept C151730666 @default.
• W4221045873 hasConcept C203092338 @default.
• W4221045873 hasConcept C2776694085 @default.
• W4221045873 hasConcept C2778239845 @default.
• W4221045873 hasConcept C2778292576 @default.
• W4221045873 hasConcept C2780110267 @default.
• W4221045873 hasConcept C2781303535 @default.
• W4221045873 hasConcept C2781451048 @default.
• W4221045873 hasConcept C530470458 @default.
• W4221045873 hasConcept C535046627 @default.
• W4221045873 hasConcept C71924100 @default.
• W4221045873 hasConcept C86803240 @default.
• W4221045873 hasConceptScore W4221045873C121608353 @default.
• W4221045873 hasConceptScore W4221045873C126322002 @default.
• W4221045873 hasConceptScore W4221045873C141071460 @default.
• W4221045873 hasConceptScore W4221045873C143998085 @default.
• W4221045873 hasConceptScore W4221045873C146357865 @default.
• W4221045873 hasConceptScore W4221045873C151730666 @default.
• W4221045873 hasConceptScore W4221045873C203092338 @default.
• W4221045873 hasConceptScore W4221045873C2776694085 @default.
• W4221045873 hasConceptScore W4221045873C2778239845 @default.
• W4221045873 hasConceptScore W4221045873C2778292576 @default.
• W4221045873 hasConceptScore W4221045873C2780110267 @default.
• W4221045873 hasConceptScore W4221045873C2781303535 @default.
• W4221045873 hasConceptScore W4221045873C2781451048 @default.
• W4221045873 hasConceptScore W4221045873C530470458 @default.
• W4221045873 hasConceptScore W4221045873C535046627 @default.
• W4221045873 hasConceptScore W4221045873C71924100 @default.
• W4221045873 hasConceptScore W4221045873C86803240 @default.
• W4221045873 hasIssue "4_Supplement" @default.
• W4221045873 hasLocation W42210458731 @default.
• W4221045873 hasOpenAccess W4221045873 @default.
• W4221045873 hasPrimaryLocation W42210458731 @default.
• W4221045873 hasRelatedWork W1718066741 @default.
• W4221045873 hasRelatedWork W1914432880 @default.
• W4221045873 hasRelatedWork W1976837208 @default.
• W4221045873 hasRelatedWork W2024856282 @default.
• W4221045873 hasRelatedWork W2070691864 @default.
• W4221045873 hasRelatedWork W2131322929 @default.
• W4221045873 hasRelatedWork W2279605172 @default.
• W4221045873 hasRelatedWork W2410047408 @default.
• W4221045873 hasRelatedWork W4285398041 @default.
• W4221045873 hasRelatedWork W4310004332 @default.
• W4221045873 hasVolume "82" @default.
• W4221045873 isParatext "false" @default.
• W4221045873 isRetracted "false" @default.
• W4221045873 workType "article" @default.